Affordable Access

deepdyve-link
Publisher Website

Comparative Analysis of Human Mesenchymal Stem Cells Derived From Bone Marrow, Placenta, and Adipose Tissue as Sources of Cell Therapy.

Authors
  • Jeon, Young-Joo1
  • Kim, Jumi2
  • Cho, Jin Hyoung1
  • Chung, Hyung-Min3
  • Chae, Jung-Il1
  • 1 Department of Dental Pharmacology, School of Dentistry and Institute of Oral Bioscience, BK21 plus, Chonbuk National University, Jeonju, 561-756, Republic of Korea. , (North Korea)
  • 2 Samsung Advanced Institute of Technology, Well Aging Research Center, Suwon, Republic of Korea. , (North Korea)
  • 3 Department of Stem Cell Biology, School of Medicine, Konkuk University, Seoul, Republic of Korea. , (North Korea)
Type
Published Article
Journal
Journal of Cellular Biochemistry
Publisher
Wiley (John Wiley & Sons)
Publication Date
May 01, 2016
Volume
117
Issue
5
Pages
1112–1125
Identifiers
DOI: 10.1002/jcb.25395
PMID: 26448537
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Various source-derived mesenchymal stem cells (MSCs) with multipotent capabilities were considered for cell therapeutics of incurable diseases. The applicability of MSCs depends on the cellular source and on their different in vivo functions, despite having similar phenotypic and cytological characteristics. We characterized MSCs from different sources, including human bone marrow (BM), placenta (PL), and adipose tissue (AT), in terms of the phenotype, surface antigen expression, differentiation ability, proteome reference map, and blood flow recovery in a hindlimb ischemic disease model. The MSCs exhibit different differentiation potentials depending on the cellular source despite having similar phenotypic and surface antigen expression. We identified approximately 90 differentially regulated proteins. Most up- or down-regulated proteins show cytoskeletal or oxidative stress, peroxiredoxin, and apoptosis roles according to their functional involvement. In addition, the PL-MSCs retained a higher therapeutic efficacy than the BM- and AT-MSCs in the hindlimb ischemic disease model. In summary, we examined differentially expressed key regulatory factors for MSCs that were obtained from several cellular sources and demonstrated their differentially expressed proteome profiles. Our results indicate that primitive PL-MSCs have biological advantages relative to those from other sources, making PL-MSCs a useful model for clinical applications of cell therapy. © 2015 Wiley Periodicals, Inc.

Report this publication

Statistics

Seen <100 times